This is achieved by accelerating the ubiquitin-mediated degradation of Axin1 and liberating the transcriptional expression of the key enzyme lactate dehydrogenase A (LDHA) to modulate the levels of glycolysis, allowing the malignant progression of BLCA. The gene discussed is AXIN1; the disease is bladder transitional cell carcinoma.